Psilocybin for Well-being

(PRISMatic Trial)

This trial explores how psilocybin, a compound in certain mushrooms, affects mood and well-being. Researchers are testing whether a single dose of psilocybin acts differently when combined with pimavanserin or a placebo. Suitable participants should be healthy, right-handed adults who speak English fluently and have no history of psychedelic drug use. The goal is to understand psilocybin's impact on the brain and mood through various tests and brain scans. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this novel treatment.

You will need to stop taking any nonprescription medications, nutritional, or herbal supplements for one week before the drug session, unless approved by the study investigators. You must also abstain from any psychoactive drugs the day before and the day of the drug administration session.

Research has shown that psilocybin, a natural substance found in certain mushrooms, affects mood and mental health. Known for causing hallucinations, previous studies found that a single high dose of psilocybin can lead to lasting positive changes in mood and cognitive flexibility.

Regarding safety, psilocybin is generally well-tolerated in controlled settings with proper support. Some individuals might experience temporary side effects like nausea, dizziness, or altered perception, but these effects are usually short-lived and not harmful.

Limited research exists on the combination of psilocybin with pimavanserin. Pimavanserin, approved for treating hallucinations and delusions in Parkinson’s disease, has been studied and found safe for use in humans for other conditions.

Psilocybin is unique because it offers a novel approach to enhancing well-being by utilizing a psychedelic compound derived from certain types of mushrooms. Unlike traditional treatments for mental health conditions, which often rely on antidepressants or therapy to manage symptoms over weeks or months, psilocybin has the potential to produce rapid and lasting improvements in mood and perception with just one or two doses. Additionally, the treatment arm using pimavanserin, a drug that acts on serotonin receptors, may help modulate the psychedelic experience, potentially making it more effective or tolerable. Researchers are excited about these features because they could lead to faster, more effective relief for individuals seeking mental health support.

Studies have shown that psilocybin can significantly reduce symptoms of depression. Specifically, in people with major depressive disorder, a single 25 mg dose of psilocybin reduced depressive symptoms by about 4.6 points on a common scale. Additionally, psilocybin has been linked to large reductions in suicidal thoughts, with effects lasting several weeks. In this trial, one group of participants will receive psilocybin combined with pimavanserin, a drug that affects brain receptors, to explore whether it may enhance these mood-lifting effects. Another group will receive psilocybin with a placebo. Researchers are exploring this combination as a new way to improve well-being and mood.⁶⁷⁸⁹¹⁰